*Refresh the page if the below document does not appear.
Sun Pharma's shares regain 4 digit marks after 7 years gap
The Shares of Sun Pharmaceuticals Industries Ltd. hit a multi-year high crossing the ₹1,000 mark this year which was earlier observed in March 2015 on the BSE. So far in the year 2022, the company’s shares have gained more than 19%.
Alembic Pharma receives US FDA nod to to market Paclitaxel injections USP
The drugmaker Alembic Pharmaceuticals announced that they have received a final approval for their ANDA (Abbreviated New Drug Application) Paclitaxel injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) multiple-dose vials.
MSCI sets aside Piramal Pharma's excision from Global Standard Index
MSCI (Morgan Stanley Capital Investment) which is the global index provider has set aside the exclusion of Piramal Pharma from its Global Standard Index after the stock hit the lower trading limit. The shares of the company slipped 5% to close at ₹163.3 on the BSE.
Gland pharma's Q2 net declines 20.14% to ₹241.24 crore
Gland Pharma declared a 20.14% decline in consolidated net profit for the second quarter that ended on September 30, because of lower sales and higher expenses. The consolidated net profit for this year was ₹241.24 crores as compared to ₹302.08 crores in the same period last fiscal year.
Glenmark Pharma declines 1.43% as US FDA issues import alert on its Baddi facility
After the inspection conducted in June 2022, the US FDA issued an import alert 66-40 to the Baddi, India facility. Following this, Glenmark Pharmaceuticals fell 1.43% to 395.90. The company said that it will try to solve the issue with US FDA at the earliest.
Biocorp signs agreement with Novo Nordisk to market Mallya in Japan
The France-based company expert in the design, development, and manufacturing of innovative medical devices announced the signing of the partnership agreement with Novo Nordisk to commercialize a smartsensor non-medical device “Mallya” in Japan.
Prostate cancer treatment with Clarity Pharma's SAR-bisPSMA theranostic might be affordable
The Australia-based clinical-stage
radiopharmaceutical company has successfully
been able to treat its first patient in Phase I/II
theranostic trial testing 64Cu/67Cu SARbisPSMA theranostic product. The said product
is indicated for patients with metastatic,
castration-resistant prostate cancer (mCRPC).
